newsfilter
← Latest News
GlobeNewswire·

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

CYTK
  • Cytokinetics reported a strong U.S. launch of MYQORZO (aficamten) in late January 2026, with over 275 healthcare providers prescribing the drug to approximately 680 patients by March 31, 2026.
  • The ACACIA-HCM Phase 3 trial in non-obstructive HCM met dual primary endpoints, demonstrating statistically significant improvements in symptoms (KCCQ) and maximal exercise performance (peak VO2).
  • The European Commission approved MYQORZO for adults with symptomatic obstructive HCM, with commercial readiness activities completed for a Q2 2026 launch in Germany.
  • The FDA accepted the Supplemental New Drug Application for MAPLE-HCM with a PDUFA date of November 14, 2026.
  • First quarter 2026 net product revenues for MYQORZO were $4.8 million, contributing to total company revenues of $19.4 million which also included $2.6 million in collaboration revenue and $11.9 million in milestone payments.
  • The company held approximately $1.1 billion in cash, cash equivalents, and investments as of March 31, 2026, reflecting a $144 million decline from the previous quarter.
  • Research and development expenses for Q1 2026 were $95.5 million, while selling, general, and administrative expenses increased to $104.9 million due to commercial launch costs.
  • The company reported a net loss of $206.0 million for the first quarter of 2026, or $1.67 per share.
  • Clinical trials for omecamtiv mecarbil (COMET-HF), ulacamten (AMBER-HFpEF), and CK-4015089 continued or advanced during the quarter.
  • Cytokinetics launched a disease awareness campaign titled "On Track with HCM" featuring Olympic athlete Sydney McLaughlin-Levrone.